STAT+: Pharmalittle: U.S. government blunder contributed to monkeypox vax shortage; Amgen to pay $4 billion for ChemoCentryx

Top of the morning to you. Another steamy day is unfolding here at the Pharmalot campus, where the short person will soon leave for a day of summertime fun. As for the rest of us, well, we can only dream. But our to-do list will keep us busy, including online meetings with some interesting folks. Hopefully, you can relate. Either way, it is time to get cracking and fire up the coffee kettle. Our choice today is vanilla macadamia nut. As always, we have also gathered a few tidbits to get you going. Have a grand day and keep us in mind if you hear anything provocative or revolutionary …

The shortage of vaccines to combat a fast-growing monkeypox outbreak was caused in part because the Department of Health and Human Services failed early on to ask that bulk stocks of the vaccine it already owned be bottled for distribution, The New York Times reports. By the time the U.S. government placed its orders, the manufacturer, Bavarian Nordic, booked other clients and was unable to do the work for months, even though the U.S. government invested well over $1 billion in the vaccine’s development. The U.S. government is now distributing about 1.1 million doses, less than a third of the 3.5 million health officials estimate are needed to fight the outbreak.

Continue to STAT+ to read the full story…